UK markets closed

Hofseth BioCare ASA (0Q6H.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
8.04+8.04 (-77.53%)
At close: 02:20PM GMT

Hofseth BioCare ASA

Kipervikgata 13
Ålesund 6003
47 73 10 22 00

Full-time employees63

Key executives

NameTitlePayExercisedYear born
Mr. Jon Olav OdegardChief Exec. Officer1.7MN/AN/A
Mr. Karl Inge SlotsvikChief Operating Officer1.2MN/AN/A
Dr. Bomi FramrozeChief Scientific Officer21.73MN/A1961
Mr. James BergerChief Commercial Officer7.81MN/AN/A
Angelika FlorvaagChief Quality Officer822kN/AN/A
Dr. Crawford CurrieHead of Medical R&D and DirectorN/AN/AN/A
Dr. Tanja SchafferEVP of Global Ingredients Division & CEO of HBC Switzerland GmbHN/AN/AN/A
Mr. Matt MixterManaging Partner of Hofseth North AmericaN/AN/A1984
Dr. Olav FlatenExec.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.


Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.

Corporate governance

Hofseth BioCare ASA’s ISS governance QualityScore as of 28 November 2022 is 5. The pillar scores are Audit: 10; Board: 3; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.